Manifold Bio Secues $15M in Series A Funding

Massachusetts-based startup, Manifold Bio, has secured $15 million in funding to continue research into leveraging artificial intelligence to revolutionize cancer studies. The Series A funding round was led by TQ Ventures and saw participation from new investors including Calibrate Ventures and SK Ventures.

With a mission to modernize the tech infrastructure of clinical research organizations, Manifold Bio has developed an AI-based platform that streamlines manual workflows and reduces administrative burdens for cancer centers. This platform, known as the mDesign™ Platform, accelerates the time to insights from months to minutes, marking a significant advancement in cancer research.

Vinay Seth Mohta, CEO and co-founder of Manifold Bio, highlights the critical need for such innovation in healthcare. By moving away from legacy technologies like Excel spreadsheets, Manifold Bio aims to provide researchers with a purpose-built tech infrastructure that enhances efficiency and productivity.

Supported by this latest funding round, Manifold Bio is poised to expand its partnerships with healthcare organizations and invest in research and development to further enhance its platform’s capabilities. Early adopters, including Indiana University Melvin and Bren Simon Comprehensive Cancer Center and Winship Cancer Institute of Emory University, have already witnessed the transformative impact of Manifold Bio’s technology.

One of the key features of Manifold Bio’s platform is its ability to unify vast amounts of healthcare data into a single platform, facilitating seamless collaboration and data analysis. This not only accelerates research studies but also reduces costs and manual efforts associated with traditional research workflows.

Anna Maria Storniolo, M.D., medical director at IU Melvin and Bren Simon Comprehensive Cancer Center, praises Manifold Bio’s platform as a game-changer in cancer research. With the ability to respond to research requests in minutes rather than weeks, researchers can now conduct studies with unprecedented speed and efficiency.

Looking ahead, Manifold Bio remains committed to pushing the boundaries of AI technology in healthcare. With a focus on advancing data curation and analysis, Manifold Bio aims to empower researchers with even more advanced tools and capabilities in the near future.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts